<DOC>
	<DOCNO>NCT00099788</DOCNO>
	<brief_summary>MERLIN-TIMI 36 multi-national , double-blind , randomize , placebo-controlled , parallel-group clinical trial design evaluate efficacy safety ranolazine acute long-term treatment approximately 5,500 patient non-ST elevation acute coronary syndrome ( ACS ) treat standard therapy . The primary efficacy endpoint MERLIN-TIMI 36 time first occurrence element composite cardiovascular death , myocardial infarction recurrent ischemia patient non-ST elevation ACS receive standard therapy . The study also evaluate safety long-term treatment ranolazine compare placebo .</brief_summary>
	<brief_title>Metabolic Efficiency With Ranolazine Less Ischemia Non-ST Elevation Acute Coronary Syndromes</brief_title>
	<detailed_description>Morrow DA , Scirica BM , Karwatowska-Prokopczuk E , Skene A , McCabe CH , Braunwald E ; MERLIN-TIMI 36 Investigators . Evaluation novel anti-ischemic agent acute coronary syndrome : design rationale Metabolic Efficiency Ranolazine Less Ischemia Non-ST-elevation acute coronary syndrome ( MERLIN ) -TIMI 36 trial . Am Heart J . 2006 Jun ; 151 ( 6 ) :1186.e1-9 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Hospitalized nonST elevation acute coronary syndrome Ischemic symptom ( equal 5 minute ) rest within 48 hour study entry At least one additional risk factor ( e.g. , elevated cardiac enzyme , STdepression , diabetes ) Persistent acute STsegment elevation Successful revascularization qualify hospitalization , prior study entry Acute pulmonary edema , hypotension , evidence cardiogenic shock Clinically significant liver disease End stage kidney disease require dialysis Concomitant use drug know prolong QT interval , digitalis drug Use study entry drug strong inhibitor cytochrome P450 3A4 Pregnant lactate woman , woman child bear potential use acceptable form birth control Additional study entry criterion evaluate initial screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Heart Attack</keyword>
	<keyword>Angina</keyword>
	<keyword>Chest pain</keyword>
	<keyword>Ischemia</keyword>
	<keyword>Non-ST Elevation Acute Coronary Syndrome</keyword>
</DOC>